Meeting report VLPNPV: Session 5: Plant based technology

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 10, 2014, Pages 3068-3073

  Meador, Lydia R ^a   Mor, Tsafrir S ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Bluetongue virus; C Erbb 2 (human epidermal growth factor receptor 2); Cowpea mosaic virus; Hepatitis b core antigen; HIV 1; Live viral vectors; Potato virus x; Tobacco mosaic virus; Viral nanoparticles; Virus like particles

Indexed keywords

ERDOSTEINE; GAG PROTEIN; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NANOPARTICLE; PLANT VIRAL NANOPARTICLE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR; CAPSID PROTEIN; HEPATITIS B CORE ANTIGEN;

BLUETONGUE ORBIVIRUS; BOVINE PAPILLOMAVIRUS; CANCER IMMUNIZATION; CONFERENCE PAPER; COWPEA MOSAIC VIRUS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PAPILLOMA VIRUS; PARTICLE SIZE; POTEXVIRUS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TOBACCO MOSAIC VIRUS; VACCINE PRODUCTION; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; PLANT;

BLUETONGUE VIRUS; CAPSID PROTEINS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEPATITIS B CORE ANTIGENS; HUMANS; NANOPARTICLES; PLANTS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84921315550     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.979693     Document Type: Conference Paper

References (64)

1. Bessa J, Zabel F, Link A, Jegerlehner A, Hinton H, Schmitz N, Bauer M, Kündig TM, Saudan P, Bachmann MF. Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc Natl Acad Sci U S A 2012; 109:20566-71; PMID:23169669; http://dx.doi.org/10.1073/pnas.1206970109
2. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol 2012; 188:3724-33. PMID:22427639; http://dx.doi.org/10.4049/jimmunol.1103312
3. Scotti N, Rybicki EP. Virus-like particles produced in plants as potential vaccines. Expert Rev Vaccines 2013; 12:211-24; PMID:23414411; http://dx.doi.org/10.1586/erv.12.147
4. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010; 8:620-37; PMID: 20233333; http://dx.doi.org/10.1111/j.1467-7652.2010.00507.x
5. Hayden EC, Reardon S. Should experimental drugs be used in the ebola outbreak? nature news. http://www.nature.com: Nature Publishing Group, 2014.
6. Langreth R, Chen C, Nash J, Lauerman J. Ebola drug made from tobacco plant saves US aid workers. http://www.bloomberg.com/news/2014-08-05/ebola-drug-made-from-tobacco-plant-saves-u-s-aid-workers.html
7. Wilson C. The long battle to find a cure for Ebola. New Scientist 2014; 223:7; http://dx.doi.org/10.1016/S0262-4079(14)61512-8
8. Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol Bioeng 2009; 103:706-14; PMID:19309755; http://dx.doi.org/10.1002/bit.22299
9. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y. In planta engineering of viral RNA replicons: Efficient assembly by recombination of DNA modules deliveredy by Agrobacterium. Proc Natl Acad Sci 2004; 101:6852-7; PMID:15103020
10. Mor TS, Moon Y, Palmer KE, Mason HS. Geminivirus vectors for high-level expression of foregin proteins in plant cells. Biotechnol Bioeng 2003; 81:430-7; PMID:12491528
11. Sainsbury F, Lavoie PO, D'Aoust MA, Vezina LP, Lomonossoff GP. Expression of multiple proteins using full-length and deleted versions of cowpea mosaic virus RNA-2. Plant Biotechnol J 2008; 6:82-92; PMID:17986176
12. Sainsbury F, Thuenemann EC, Lomonossoff GP. pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol J 2009; 7:682-93; PMID:19627561; http://dx.doi.org/10.1111/j.1467-7652.2009.00434.x
13. Thuenemann EC, Meyers AE, Verwey J, Rybicki EP, Lomonossoff GP. A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant Biotechnol J 2013; 11:839-46; PMID:23647743; http://dx.doi.org/10.1111/pbi.12076
14. Steinmetz NF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine 2010; 6:634-41; PMID:20433947; http://dx.doi.org/10.1016/j.nano.2010.04.005
15. Yildiz I, Shukla S, Steinmetz NF. Applications of viral nanoparticles in medicine. Curr Opin Biotechnol 2011; 22:901-8; PMID:21592772; http://dx.doi.org/10.1016/j.copbio.2011.04.020
16. Hjelm BE, Kilbourne J, Herbst-Kralovetz MM. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum Vaccin Immunother 2014; 10:410-6; PMID:24280723; http://dx.doi.org/10.4161/hv.27147
17. D'Aoust MA, Couture MM, Charland N, Trepanier S, Landry N, Ors F, Vézina LP. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010; 8:607-19; PMID:20199612; http://dx.doi.org/10.1111/j.1467-7652.2009.00496.x
18. Carpenter S, Wilson A, Mellor PS. Culicoides and the emergence of bluetongue virus in northern Europe. Trends Microbiol 2009; 17:172-8; PMID:19299131; http://dx.doi.org/10.1016/j.tim.2009.01.001
19. Hartemink NA, Purse BV, Meiswinkel R, Brown HE, de Koeijer A, Elbers AR,Boender GJ, Rogers DJ, Heesterbeek JA. Mapping the basic reproduction number (R(0)) for vector-borne diseases: a case study on bluetongue virus. Epidemics 2009; 1:153-61; PMID: 21352762; http://dx.doi.org/10.1016/j.epidem.2009.05.004
20. Elbers AR, Backx A, Mintiens K, Gerbier G, Staubach C, Hendrickx G, van der Spek A. Field observations during the Bluetongue serotype 8 epidemic in 2006. II. Morbidity and mortality rate, case fatality and clinical recovery in sheep and cattle in the Netherlands. Prev Vet Med 2008; 87:31-40; PMID:18620768; http://dx.doi.org/10.1016/j.prevetmed.2008.06.003
21. Batten CA, Maan S, Shaw AE, Maan NS, Mertens PP. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res 2008; 137:56-63; PMID: 18598726; http://dx.doi.org/10.1016/j.virusres.2008.05.016
22. Maan NS, Maan S, Belaganahalli MN, Ostlund EN, Johnson DJ, Nomikou K, Mertens PP. Identification and differentiation of the twenty six bluetongue virus serotypes by RT-PCR amplification of the serotypespecific genome segment 2. PloS One 2012; 7:e32601; PMID:22389711; http://dx.doi.org/10.1371/journal.pone.0032601
23. Perez de Diego AC, Athmaram TN, Stewart M, Rodriguez-Sanchez B, Sanchez-Vizcaino JM, Noad R, Roy P. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep. PloS One 2011; 6:e26666; PMID:22046324
24. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S. Vaccines against bluetongue in Europe. Comp Immunol, Microbiol Infect Dis 2008; 31:101-20; PMID:17765305; http://dx.doi.org/10.1016/j.cimid.2007.07.006
25. Love AJ, Chapman SN, Matic S, Noris E, Lomonossoff GP, Taliansky M. In planta production of a candidate vaccine against bovine papillomavirus type 1. Planta 2012; 236:1305-13; PMID:22718313
26. Peyret H, Lomonossoff GP. The pEAQ vector series: the easy and quick way to produce recombinant proteins in plants. Plant Mol Biol 2013; 83:51-8; PMID:23479085; http://dx.doi.org/10.1007/s11103-013-0036-1
27. French TJ, Marshall JJ, Roy P. Assembly of doubleshelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol 1990; 64:5695-700; PMID:2173762
28. French TJ, Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol 1990; 64:1530-6; PMID:2157041
29. Stewart M, Dovas CI, Chatzinasiou E, Athmaram TN, Papanastassopoulou M, Papadopoulos O, Roy P. Protective efficacy of Bluetongue virus-like and subviruslike particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 2012; 30:2131-9; PMID:22285887; http://dx.doi.org/10.1016/j.vaccine.2012.01.042
30. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 2014; 6.228ra38; PMID:24648341; 10.1126/scitranslmed.3007736
31. Haynes BF, Gilbert PB, McElrath J, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425
32. Rerks-Ngarm S, Pitisuttihum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2210-20.
33. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014; 6:228ra39; PMID:24648342; http://dx.doi.org/10.1126/scitranslmed.3007730
34. Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH. Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In Vivo Virologic Control following Simian Immunodeficiency Virus Challenges of Vaccinated Rhesus Monkeys. J Virol 2012; 86:9583-9.
35. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491:406-12; PMID:23151583; http://dx.doi.org/10.1038/nature11544
36. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A. A broadly neutralizing human monoclonal antibody against gp41 of Human Immunodeficiency Virus Type1. AIDS Res Hum Retroviruses 1994; 10:1651-8; PMID:7888224; http://dx.doi.org/10.1089/aid.1994.10.1651
37. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-905; PMID:11602729; http://dx.doi.org/10.1128/JVI.75.22.10892-10905.2001
38. Kessans SA, Linhart MD, Matoba N, Mor T. Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana. Plant Biotechnol j 2013; 11:681-90; PMID:23506331; http://dx.doi.org/10.1111/pbi.12058
39. Matoba N, Griffin TA, Mittman M, Doran JD, Alfsen A, Montefiori DC, Hanson CV, Bomsel M, Mor TS. Transcytosis-blocking Abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res 2008; 6:218-29; PMID:18473785
40. Matoba N, Kajiura H, Cherni I, Doran JD, Bomsel M, Fujiyama K, Mor TS. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTBMPR. Plant Biotechnol J 2009; 7:129-45; PMID:19037902; http://dx.doi.org/10.1111/j.1467-7652.2008.00381.x
41. Shen X, Dennison SM, Liu P, Gao F, Jaeger F, Montefiori DC, Verkoczy L, Haynes BF, Alam SM, Tomaras GD. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc Natl Acad Sci U S A 2010; 107:5972-7; PMID:20231447; http://dx.doi.org/10.1073/pnas.0912381107
42. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, Liao HX, Kelsoe G, Haynes BF. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010; 107:181-6; PMID:20018688; http://dx.doi.org/10.1073/pnas.0912914107
43. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WJ, Davis SW, van der Hoeven J, Meignier B, Riviere M. NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992; 188:217-32; PMID:1566575; http://dx.doi.org/10.1016/0042-6822(92)90752-B
44. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, et al. Improved NYVAC-Based vaccine vectors. PloS One 2011; 6:e25674; PMID:22096477; http://dx.doi.org/10.1371/journal.pone.0025674
45. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, Filali-Mouhim A, Goulet JP, Loof NM, Ossendorp F, et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PloS One 2011; 6:e16819; PMID:21347234; http://dx.doi.org/10.1371/journal.pone.0016819
46. Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 2012; 8:1192-207; PMID:22906946; http://dx.doi.org/10.4161/hv.20778
47. Hansen SG, Piatak M, Jr., Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100-4; PMID: 24025770; http://dx.doi.org/10.1038/nature12519
48. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, Gilbride RM, Lewis MS, Gilliam AN, Ventura AB, et al. Cytomegalovirus vectors violate CD8C T cell epitope recognition paradigms. Science 2013; 340:1237874; PMID:23704576; http://dx.doi.org/10.1126/science.1237874
49. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012; 8:147-66; PMID:21703993; http://dx.doi.org/10.1016/j.nano.2011.05.016
50. Kaiser CR, Flenniken ML, Gillitzer E, Harmsen AL, Harmsen AG, Jutila MA, Douglas T, Young MJ. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomedicine 2007; 2:715-33; PMID:18203438
51. Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, Finn MG, Manchester M. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release 2007; 120:41-50; PMID:17512998; http://dx.doi.org/10.1016/j.jconrel.2007.04.003
52. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012; 14:1-16; PMID:22524388; http://dx.doi.org/10.1146/annurev-bioeng-071811-150124
53. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape, and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010; 7:479-95; PMID:20331355; http://dx.doi.org/10.1517/17425240903579971
54. Daum N, Tscheka C, Neumeyer A, Schneider M. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4:52-65; PMID:22140017; http://dx.doi.org/10.1002/wnan.165
55. Wen AM, Rambhia PH, French RH, Steinmetz NF. Design rules for nanomedical engineering: from physical virology to the applications of virus-based materials in medicine. J biol phys 2013; 39:301-25; PMID:23860875; http://dx.doi.org/10.1007/s10867-013-9314-z
56. Rubin I, Yarden Y. The basic biology of HER2. Annals of Oncology 2001; 12:S3-S8; http://dx.doi.org/10.1093/annonc/12.suppl-1.S3
57. Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013; 24:1740-8; PMID:23585514; http://dx.doi.org/10.1093/annonc/mdt133
58. Shukla S, Ablack AL, Wen AM, Lee KL, Lewis JD, Steinmetz NF. Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol pharm 2013; 10:33-42; PMID:22731633; http://dx.doi.org/10.1021/mp300240m
59. Wen AM, Steinmetz NF. The aspect ratio of nanoparticle assemblies and the spatial arrangement of ligands can be optimized to enhance the targeting of cancer cells. Adv Healthc Mater 2014; 3:1739-44; PMID:24729309; http://dx.doi.org/10.1002/adhm.201400141
60. Montague NP, Thuenemann EC, Saxena P, Saunders K, Lenzi P, Lomonossoff GP. Recent advances of Cowpea mosaic virus-based particle technology. Hum Vaccin 2011; 7:383-90; PMID:21368585
61. Sainsbury F, Saunders K, Aljabali AA, Evans DJ, Lomonossoff GP. Peptide-controlled access to the interior surface of empty virus nanoparticles. Chembiochem 2011; 12:2435-40; PMID:21953809; http://dx.doi.org/10.1002/cbic.201100482
62. Saunders K, Sainsbury F, Lomonossoff GP. Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology 2009; 393:329-37; PMID:19733890; http://dx.doi.org/10.1016/j.virol.2009.08.023
63. Bruckman MA, Randolph LN, VanMeter A, Hern S, Shoffstall AJ, Taurog RE, Steinmetz NF. Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology 2014; 449:163-73; PMID:24418549; http://dx.doi.org/10.1016/j.virol.2013.10.035
64. Butler JG. The current picture of the structure and assembly of tobacco mosaic virus. J General Virology 1984; 65:253-79; PMID:6363621; http://dx.doi.org/10.1099/0022-1317-65-2-253